- author = "Jing Liang and Zong-Wei Li and Ze-Ning Sun and Ying Bi and Han Cheng and Tao Zeng2 and Wei-Feng Guo",
- title = "Latent space search based multimodal optimization with personalized edge-network biomarker for multi-purpose early disease prediction",
- journal = "Briefings in Bioinformatics",
- year = "2023",
- volume = "24",
- number = "6",
- pages = "bbad364",
- month = oct,
- keywords = "genetic algorithms, genetic programming, MMPDENB-RBM, multimodal optimization, latent space research, personalised dynamic edge-network biomarkers, multi-purpose disease prediction, drug targets",
- ISSN = "1477-4054",
- eprint = "https://academic.oup.com/bib/article-pdf/24/6/bbad364/52107912/bbad364.pdf",
-
URL = "
https://doi.org/10.1093/bib/bbad364",
-
DOI = "
doi:10.1093/bib/bbad364",
- size = "17 pages",
- abstract = "Considering that cancer is resulting from the comutation of several essential genes of individual patients, researchers have begun to focus on identifying personalized edge-network biomarkers (PEBs) using personalized edge-network analysis for clinical practice. However, most of existing methods ignored the optimization of PEBs when multimodal biomarkers exist in multi-purpose early disease prediction (MPEDP). To solve this problem, this study proposes a novel model (MMPDENB-RBM) that combines personalized dynamic edge-network biomarkers (PDENB) theory, multimodal optimization strategy and latent space search scheme to identify biomarkers with different configurations of PDENB modules (i.e. to effectively identify multimodal PDENBs). The application to the three largest cancer omics datasets from The Cancer Genome Atlas database (i.e. breast invasive carcinoma, lung squamous cell carcinoma and lung adenocarcinoma) showed that the MMPDENB-RBM model could more effectively predict critical cancer state compared with other advanced methods. And, our model had better convergence, diversity and multimodal property as well as effective optimization ability compared with the other state-of-art methods. Particularly, multimodal PDENBs identified were more enriched with different functional biomarkers simultaneously, such as tissue-specific synthetic lethality edge-biomarkers including cancer driver genes and disease marker genes. Importantly, as our aim, these multimodal biomarkers can perform diverse biological and biomedical significances for drug target screen, survival risk assessment and novel biomedical sight as the expected multi-purpose of personalized early disease prediction. In summary, the present study provides multimodal property of PDENBs, especially the therapeutic biomarkers with more biological significances, which can help with MPEDP of individual cancer patients.",
-
notes = "
State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou 7510060, China.",
